Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06041386 · ClinicalTrials.gov registry record · Phase 4
REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study
A Phase 4 study of Asthma, sponsored by GlaxoSmithKline.
- Active
- Registry status
- Phase 4
- Development phase
- 336
- Enrollment target
- 20
- Study locations
NCT06041386 is a Phase 4 study of Asthma that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 336 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT06041386, a Phase 4 study of Asthma, is active but no longer recruiting, sponsored by GlaxoSmithKline.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 336 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a prospective, real-world, single arm, global, multi-centre study to evaluate the effect of timely treatment with mepolizumab (NUCALA) to achieve clinical remission in adult participants with severe asthma with an eosinophilic phenotype (SA-EP).
Conditions Studied
Interventions
- DRUG Mepolizumab
- OTHER Spirometry
Study Locations (20)
Florida
- GSK Investigational Site - Homestead
- GSK Investigational Site - Jacksonville
- GSK Investigational Site - Miami
- GSK Investigational Site - Plantation
California
- GSK Investigational Site - La Jolla
- GSK Investigational Site - Newport Beach
Colorado
- GSK Investigational Site - Aurora
- GSK Investigational Site - Colorado Springs
Georgia
- GSK Investigational Site - Adairsville
- GSK Investigational Site - Columbus
Kentucky
- GSK Investigational Site - Lexington
- GSK Investigational Site - Owensboro
Maryland
- GSK Investigational Site - Glenn Dale
- GSK Investigational Site - Towson
Connecticut
- GSK Investigational Site - New Haven
Louisiana
- GSK Investigational Site - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 336 participants |
| Start Date | 2024-03-20 |
| Est. Completion | 2028-06-14 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06041386
The ClinicalTrials.gov registry entry for NCT06041386 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 336 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (78% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Mepolizumab is the first listed.
NCT06041386 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT06041386 about?
NCT06041386 is a clinical study titled "REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study". This is a prospective, real-world, single arm, global, multi-centre study to evaluate the effect of timely treatment with mepolizumab (NUCALA) to achieve clinical remission in adult participants with severe asthma with an eosinophilic phenotype (SA-EP).
What is the current status of trial NCT06041386?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 336 participants. The study started on 2024-03-20. Estimated completion is 2028-06-14.
What conditions does trial NCT06041386 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT06041386?
The interventions under investigation include: Mepolizumab (DRUG), Spirometry (OTHER).
Who is sponsoring clinical trial NCT06041386?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06041386 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
-
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 4
-
Viral Infection in Asthma (VIA) Study
RECRUITING · Phase 4
-
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
RECRUITING · Phase 4
-
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
RECRUITING · Phase 4
-
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.